Genovis
Carthesian Therapeutics terminates Genovis Licence Agreement
Substantial resources have already been invested in the project, which now will be for the benefit of Genovis, amongst other items second and third generation of the Xork enzyme with corresponding patent applications. Currently there are no known pre-clinical or clinical data that suggest that there should not be future opportunities for therapeutic applications of Xork.
"We will now regain full rights to our proprietary Xork enzyme and we can now act on business opportunities with other partners within gene therapy and autoimmune diseases. We have several ongoing partner discussions and we have learned there is a great interest in finding new solutions to neutralizing antibodies." says Fredrik Olsson, CEO, Genovis.
This disclosure contains information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-03-2024 17:26 CET.
| Datum | 2024-03-14, kl 17:25 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!